Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
Status:
Completed
Trial end date:
2024-04-03
Target enrollment:
Participant gender:
Summary
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are
typically treated by selectively weakening specific muscles with small quantities of
botulinum toxin. The purpose of this study is to evaluate the safety and efficacy of
AGN-151586 over a range of doses for the treatment of moderate to severe GL in Japanese
participants.
AGN-151586 is an investigational product being developed for the treatment of GL.
Participants are randomly assigned to receive AGN-151586 or placebo. There is 1 in a 4 chance
that participants will receive placebo. Around 24 adult participants with moderate to severe
GL will be enrolled in the study in approximately 2 sites in Japan.
Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular
injections to the glabellar complex on Day 1. The duration of the study will be approximately
6 weeks.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.